MX9307886A - Composicion farmaceutica y proceso para su preparacion. - Google Patents

Composicion farmaceutica y proceso para su preparacion.

Info

Publication number
MX9307886A
MX9307886A MX9307886A MX9307886A MX9307886A MX 9307886 A MX9307886 A MX 9307886A MX 9307886 A MX9307886 A MX 9307886A MX 9307886 A MX9307886 A MX 9307886A MX 9307886 A MX9307886 A MX 9307886A
Authority
MX
Mexico
Prior art keywords
rapamycin
blood
treatment
preparation
pharmaceutical composition
Prior art date
Application number
MX9307886A
Other languages
English (en)
Inventor
Jay Joseph Armstrong
Surendra Nath Sehgal
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of MX9307886A publication Critical patent/MX9307886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta invención se relaciona con una técnica para tratar a un mamífero con rapamicina, la cual comprende la extracción de la sangre del paciente, el tratamiento de los elementos que forman la sangre con rapamicina la cual se une de manera rápida y reversible con los eritrocitos, y regresar las células sanguíneas tratadas al sistema circulatorio del paciente para el tratamiento de cualquiera de las enfermedades, síndromes, condiciones o trastornos, o respuestas inmunes las cuales responden al tratamiento con rapamicina. De manera alternativa, la sangre tratada con rapamicina se puede obtener de un mamífero donador compatible hematológicamente.
MX9307886A 1992-12-22 1993-12-13 Composicion farmaceutica y proceso para su preparacion. MX9307886A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/998,065 US5482945A (en) 1992-12-22 1992-12-22 Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements

Publications (1)

Publication Number Publication Date
MX9307886A true MX9307886A (es) 1994-07-29

Family

ID=25544702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9307886A MX9307886A (es) 1992-12-22 1993-12-13 Composicion farmaceutica y proceso para su preparacion.

Country Status (9)

Country Link
US (4) US5482945A (es)
EP (1) EP0604143B1 (es)
JP (1) JP3482230B2 (es)
AT (1) ATE164070T1 (es)
CA (1) CA2110939A1 (es)
DE (1) DE69317535T2 (es)
ES (1) ES2114594T3 (es)
GR (1) GR3026582T3 (es)
MX (1) MX9307886A (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153186A (en) * 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US6916471B2 (en) 1995-09-15 2005-07-12 Duke University Red blood cells loaded with S-nitrosothiol and uses therefor
JPH09165339A (ja) * 1995-10-27 1997-06-24 American Home Prod Corp ラパマイシンを付与したドナー脾細胞を用いる臓器移植の延長
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
CA2651542A1 (en) * 2006-05-03 2007-12-13 Therakos, Inc. Methods for treating diseases involving stress-related diseases and conditions
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) * 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
GB0909754D0 (en) * 2009-06-05 2009-07-22 Magnani Mauro Drug delivery systems
AU2010311515B2 (en) * 2009-10-27 2014-02-20 Erytech Pharma Composition to induce specific immune tolerance
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
US5547959A (en) 1996-08-20
GR3026582T3 (en) 1998-07-31
JPH06199671A (ja) 1994-07-19
ATE164070T1 (de) 1998-04-15
JP3482230B2 (ja) 2003-12-22
US5543418A (en) 1996-08-06
EP0604143A2 (en) 1994-06-29
DE69317535D1 (de) 1998-04-23
EP0604143B1 (en) 1998-03-18
EP0604143A3 (en) 1994-09-28
US5482945A (en) 1996-01-09
US5622963A (en) 1997-04-22
DE69317535T2 (de) 1998-10-01
ES2114594T3 (es) 1998-06-01
CA2110939A1 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
MX9307886A (es) Composicion farmaceutica y proceso para su preparacion.
ATE74282T1 (de) Methode zur behandlung von plasma und dessen produkten.
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE3886254D1 (de) Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat.
ATE215967T1 (de) Aus harn isolierte antikoagulierende verbindung
DE58904683D1 (de) Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
DK532087A (da) Farmaceutiske praeparater til behandling af hjernelidelser paa funktional og organisk basis
NO880292D0 (no) Fremgangsmaate for behandling av humle.
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
IE811612L (en) Thiazoles
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
IT8620561A0 (it) Procedimento e dispositivo per il trattamento di prodotti di uovo, o relativi composti, per prolungare la durata dei prodotti medesimi.
NO871507L (no) Fremgangsmaate for fremstilling av arylsubstituerte nafthyridin- og pyridopyrazinderivater.
DK0486586T3 (da) Kynurensyrederivater, fremstilling deraf og farmaceutiske præparater, der indeholder dem
DE69023331D1 (de) Behandeltes hämoglobin und dessen herstellung.
ATE91626T1 (de) Pyridin- oder pyridazinderivate als kardioprotektiva und zur behandlung von ischaemischen beschwerden und herstellungsprozess.
ATE85522T1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
ATE89727T1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
DE58904510D1 (de) Optisch reines dexniguldipin und dessen derivate zur behandlung von tumorerkrankungen.
DE3887137D1 (de) Mittel zur prophylaxe und behandlung einer pankreatischen erkrannkung oder dergleichen.
SE8603746D0 (sv) System for extracorporeal blodbehandling
IT9041714A0 (it) Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: ESPERION THERAPEUTICS INC.

MM Annulment or lapse due to non-payment of fees